Global Cholera Vaccines Oral Live Market Size By Type (Dukoral, Shanchol), By Application (Hospital, Scientific Research), By Region, And Segment Forecasts, 2023 to 2032

The Global Cholera Vaccines Oral Live Market was valued at USD 182.4 million in 2023 and is projected to surpass USD 385.7 million by 2031, growing at a CAGR of 9.6% during the forecast period from 2023 to 2031. This growth is attributed to the increasing prevalence of cholera in endemic regions, rising global initiatives to combat waterborne diseases, and heightened awareness of preventive healthcare. Oral live cholera vaccines are gaining traction due to their ease of administration, effectiveness, and suitability for large-scale immunization programs, particularly in low-resource settings.

Drivers:

1. Rising Incidence of Cholera in Endemic Regions

The persistent burden of cholera in regions with inadequate sanitation and water access—especially in parts of Africa, South Asia, and Latin America—continues to fuel demand for oral vaccines. These vaccines are a critical component in outbreak control and long-term prevention strategies.

2. Global Health Initiatives and Government Support

Support from international health organizations like WHO and GAVI for mass immunization campaigns and stockpiling programs significantly boosts market growth. Governmental investments in public health infrastructure are further reinforcing vaccine demand.

3. Advantages of Oral Live Vaccines

Compared to injectable vaccines, oral live vaccines offer non-invasive delivery, fewer logistical challenges, and improved patient compliance. This makes them ideal for rapid deployment in outbreak scenarios and public immunization drives.

Restraints:

1. Cold Chain Dependency and Storage Challenges

Live vaccines typically require stringent cold chain conditions, which pose significant distribution challenges in remote or underdeveloped regions, potentially hindering mass adoption.

2. Vaccine Hesitancy and Limited Awareness

Cultural beliefs, misinformation, and general vaccine hesitancy can impact uptake, especially in rural populations. Inadequate awareness about the severity of cholera also plays a role in limiting vaccination rates.

Opportunity:

1. Expansion in Emerging Markets

Regions in Africa, Southeast Asia, and parts of Latin America present untapped opportunities due to rising healthcare funding, international partnerships, and increasing recognition of cholera as a public health threat.

2. Development of Thermostable Vaccines

Ongoing R&D into thermostable oral cholera vaccines can significantly ease cold chain constraints, enabling broader reach and improving cost-efficiency of mass immunization programs.

Market by System Type Insights:

The monovalent vaccine segment held the largest share in 2023, primarily driven by its targeted use in outbreak response and stockpile distribution. However, the bivalent oral vaccine segment is expected to register the fastest growth over the forecast period due to its broader protection and WHO prequalification, making it a preferred option in global immunization programs.

Market by End-use Insights:

The public healthcare institutions segment accounted for over 65% of the market in 2023, owing to government-led vaccination campaigns and humanitarian outreach by global organizations. The travel clinics and private hospitals segment is anticipated to grow steadily, driven by rising demand among international travelers and migrant workers.

Market by Regional Insights:

Asia-Pacific emerged as the leading regional market in 2023, fueled by recurring cholera outbreaks and government-supported immunization drives in countries like India and Bangladesh. Africa is expected to witness the highest growth rate during the forecast period due to worsening climate-linked cholera conditions and expanded funding from international health bodies. Meanwhile, Latin America and Middle East & Africa also offer promising growth opportunities due to improving healthcare infrastructure.

Competitive Scenario:

Key players operating in the Global Cholera Vaccines Oral Live Market include:

Valneva SE

EuBiologics Co., Ltd.

Shantha Biotechnics (a Sanofi company)

PaxVax, Inc.

Johnson & Johnson Services, Inc.

Hilleman Laboratories

Emergent BioSolutions Inc.

These players focus on expanding production capacity, receiving WHO prequalification, and entering strategic public-private partnerships to enhance their global reach. For instance:

In 2023, EuBiologics announced the expansion of its manufacturing facility to meet the growing demand for its WHO-prequalified Euvichol vaccine.

Valneva SE, in 2024, initiated clinical trials for a next-generation thermostable cholera vaccine targeting rural mass immunization programs.

In 2025, Hilleman Laboratories collaborated with international NGOs to develop low-cost oral vaccines for endemic regions in Africa.

Scope of Work – Global Cholera Vaccines Oral Live Market

Key Market Developments:

2023 – EuBiologics received WHO PQS (Performance, Quality and Safety) certification for its updated Euvichol-Plus formulation, enhancing procurement prospects by global agencies.

2024 – Valneva partnered with a multinational NGO to supply oral cholera vaccines for refugee camps in the Middle East.

2025 – Shantha Biotechnics scaled up vaccine production to support India’s National Immunization Program.

FAQs:

1) What is the current market size of the Global Cholera Vaccines Oral Live Market?

The market was valued at USD 182.4 million in 2023.

2) What is the major growth driver of the Global Cholera Vaccines Oral Live Market?

The major growth driver is the rising incidence of cholera and increasing global immunization efforts.

3) Which is the largest region during the forecast period in the Global Cholera Vaccines Oral Live Market?

Asia-Pacific is expected to be the largest region throughout the forecast period.

4) Which segment accounted for the largest market share in Global Cholera Vaccines Oral Live Market?

The monovalent oral vaccine segment held the largest market share in 2023.

5) Who are the key market players in the Global Cholera Vaccines Oral Live Market?

Key players include Valneva SE, EuBiologics, Shantha Biotechnics, PaxVax, and Johnson & Johnson Services.